This research is a Phase 3 study, meaning it's in the later stages of testing. It lasts for 6 weeks and is a randomized, double-blind, placebo-controlled trial. This means participants are randomly assigned to receive either the actual treatment or a placebo, and neither they nor the researchers know who gets which. The study focuses on people with schizophrenia who aren't fully helped by their current medication. Schizophrenia is a mental health condition that can cause hallucinations, delusions, and other thought disorders. The study tests a new treatment called KarXT (a mix of xanomeline and trospium chloride) to see if it helps more than a placebo.

Key Points to Consider:

• The study requires outpatient visits, meaning participants don't stay overnight.
• The study involves taking the medication twice daily.
• Participants need to have a stable living situation and a reliable caregiver.